4.7 Article

Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis

期刊

CANCER LETTERS
卷 302, 期 1, 页码 54-62

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.12.013

关键词

Chemokine; Granulocyte chemotactic protein-2 (GCP-2); Melanoma

类别

资金

  1. Centers of Excellence of the K.U. Leuven [EF/05/15]
  2. Concerted Research Actions (G.O.A.) of the Regional Government of Flanders
  3. Fund for Scientific Research of Flanders (F.W.O. Vlaanderen)
  4. Fonds National de la Recherche Scientifique Medicale (FRSM, Belgique)
  5. European Union [INNOCHEM]
  6. Interuniversity Attraction Poles Program (I.A.P.)-Belgian Science Policy

向作者/读者索取更多资源

The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据